Clinical outcome in adults with Covid-19, treated with early antibiotic therapy. A retrospective cohort in the CMDLT January-June 2021.

Abstract

The prevalence of antibiotic prescription during the COVID-19 pandemic was represented by at least three quarters of the patients. Through the months of work in the Covid19-CMDLT area, we have been led to consider how this early use of antibiotics in adult patients with viral pneumonia by SARS-CoV-2 (COVID-19) influences various clinical outcomes. This observational retrospective cohort study, with a 1:1 ratio. We analyzed 144 patients corresponding to the CASES who received antibiotic therapy prior to hospitalization, and 144 CONTROLS randomly drawn, including demographic variables, symptoms, comorbidities, blood cultures, emerging parasites, urine and sputum, days of hospitalization and clinical outcome that included improvement or death. In this study for statistical analysis we apply the Chi-square test. A population of 288 patients was analyzed, 59.7% of the population corresponding to the female group and 40.2%, there were 58 deaths, 52% in the case group and 48% in the control group. In days of hospitalization, the average was 6, registering 37.5%, of which 39.5% belonged to the case group, and 35.4% to the controls. Regarding associated infections corroborated by bacteriological studies, it was 12.5% ​​of the total population. In conclusion, despite having statistically significant results, it was appreciated that in proportion there is a difference in favor of the use of antibiotics having a worse outcome, for which it is suggested that future studies be carried out where multicenters and a larger number of population are compared.